Scientific Reports
July 11, 2026
Monnica T. Williams, Sonya C. Faber, Jordan Sloshower et al.
This preliminary study explored the effects of MDMA-assisted therapy on trauma symptoms related to discrimination, as measured by the Trauma Symptoms of Discrimination Scale (TSDS). A total of five diverse participants, who experienced multiple types of discrimination (e.g., gender, racial/ethnic, social class, age, sexual orientation), were assessed before and after treatment. A paired-samples...
Psychedelic Medicine
January 20, 2025
Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano et al.
9 citations
Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for...
Journal of Psychedelic Studies
2025
Beatriz Caiuby Labate, Henrique Fernandes Antunes, Jamie Beachy et al.
6 citations
Abstract This article critically addresses one of the most pressing questions of the current moment of the psychedelic wave: Is mainstreaming psychedelics a good thing? Our aim is not to provide a simple “yes” or “no” as an answer but to explore the tensions, controversies, disparities, inequalities, and risks that have risen in the last decades. We discuss the limits of psychedelic science as...
Ponto Urbe
December 27, 2024
Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.
Em fevereiro de 2023, a Drug Enforcement Administration (DEA) divulgou um documento para a equipe jurídica que representa a Church of the Eagle and the Condor (“CEC”). Essa divulgação ocorreu dois anos depois que a igreja, em conjunto com o Chacruna Institute, enviou duas solicitações baseadas na lei de liberdade de informação [Freedom Of Information Act] à DEA e ao Departamento de Justiça...
Scientific Reports
April 17, 2024
Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss et al.
56 citations
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexibility may mediate therapeutic...
JAMA
August 31, 2023
Charles L. Raison, Gerard Sanacora, Joshua Woolley et al.
493 citations
Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...
Journal of Psychopharmacology
June 30, 2023
Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al.
47 citations
Background: Evidence suggests that serotonergic psychedelics (e.g. psilocybin), have rapid-acting and long-lasting antidepressant effects after a single dose. However, the mechanism underlying these effects remain unclear. One proposed mechanism is that these drugs promote neuroplasticity. However, this has not been conclusively demonstrated in humans. Aims: We hypothesized that relative to...
Journal of Psychedelic Studies
June 9, 2023
Beatriz Caiuby Labate, Anna O. Ermakova, Jordan Sloshower et al.
1 citation
Abstract On February 2023, the Drug Enforcement Administration (DEA) released a document to the legal team representing the Church of the Eagle and the Condor (“CEC”). This disclosure came two years after the church, in conjunction with Chacruna Institute, submitted two FOIA requests to the DEA and the Department of Justice requesting all records pertaining to ayahuasca. This report, titled...
Journal of Psychopharmacology
March 20, 2023
Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al.
153 citations
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with...
November 15, 2022
Jeffrey Guss, Robert Krause, Jordan Sloshower
preprint
This is the French translation of the Yale Manual for Psilocybin-Assisted Therapy of Depression. Le Manuel de Yale pour le traitement thérapeutique de la dépression assisté par la psilocybine fournit aux chercheurs et aux thérapeutes des méthodes, une structure et des domaines à prendre en compte concernant l'utilisation de la thérapie assistée par les psychédéliques dans le traitement du...
Journal of Medical Ethics
July 12, 2021
Dana Strauss, Sara de la Salle, Jordan Sloshower et al.
70 citations
There is a growing resurgence in the study of psychedelic medicines for the treatment of mental health and substance use disorders. However, certain early investigations are marred by questionable research methods, abuses against research participants, and covert Central Intelligence Agency financial involvement. The purpose of this study was to understand how and to what extent people of...
August 13, 2020
Jeffrey Guss, Robert Krause, Jordan Sloshower
86 citations
preprint
The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therapeutic framework for...
Journal of Contextual Behavioral Science
2020
Jordan Sloshower, Jeffrey Guss, Robert Krause et al.
168 citations
Abstract Psychedelic-assisted therapy is based on the premise that psychedelic substances can act as catalysts or adjuncts to psychotherapeutic processes. Recent clinical trials involving psychedelic-assisted therapy have generally employed a similar three-part structure consisting of preparation, support during the dosing sessions, and subsequent “integration.” However, the content of these...
William L. Prueitt, Jordan Sloshower
preprint
This is a syllabus of an elective course on psychedelic medicine designed and offered by the authors, via the Yale Psychedelic Science Group. This first iteration is being offered from Octo-Dec 2020. This elective is primarily a reading seminar focused on participatory group discussions of 2-3 assigned readings per class. The course begins with a discussion of indigenous uses of psychedelic...